Spatz Adjustable Balloon for Obesity (SABO) (SABO)
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Spatz3 Adjustable Balloon
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring weight loss
Eligibility Criteria
Inclusion Criteria:
- Age 22 - 65
- BMI ≥ 30 and <40
- Willingness to comply with the substantial lifelong dietary restrictions required by the procedure
- History of obesity (BMI ≥ 30) for at least 2 years
- History of failure with non-surgical weight loss methods
- Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory tests, completing diet counseling
- Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete all routine follow- up visits
- Ability to give informed consent
- Women of childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods. Acceptable birth control methods are limited to hormonal contraceptives (oral, flexible vaginal ring, skin patch, injection), diaphragms, IUDs, condoms with or without spermicide, and voluntary abstinence. The method of birth control must be documented and verified at follow-up. Should a treatment arm subject become pregnant during the implantation period, the balloon will be extracted during the second trimester - the timing of which will be determined via consultation with the subject's obstetrician.
Exclusion Criteria:
- Prior gastrointestinal surgery with sequelae, i.e. obstruction, and/or adhesive peritonitis or known abdominal adhesions.
- Prior open or laparoscopic bariatric surgery.
- Prior surgery of any kind on the esophagus, stomach or any type of hiatal hernia surgery.
- Any inflammatory disease of the gastrointestinal tract including esophagitis, Barrett's esophagus, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease.
- Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses.
- A gastric mass.
- A hiatal hernia > 2cm or severe or intractable gastro-esophageal reflux symptoms.
- Acid reflux symptoms to any degree that require more than one medication for symptom control.
- A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the balloon alongside the endoscope.
- Achalasia or any other severe esophageal motility disorder that may pose a safety risk during the removal of the device
- Severe coagulopathy.
- Insulin-dependent diabetes (either Type 1 or Type 2) or a significant likelihood of requiring insulin treatment in the following 12 months.
- Subjects with any serious health condition unrelated to their weight that would increase the risk of endoscopy
- Chronic abdominal pain
- Motility disorders of the GI tract such as gross esophageal motility disorders, gastroparesis or intractable constipation
- Hepatic insufficiency or cirrhosis
- Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with follow up visits and removal of the device after 8 months.
- Alcoholism or drug addiction.
- Patients unwilling to participate in an established medically-supervised diet and behavior modification program, with routine medical follow-up.
- Patients receiving daily prescribed treatment with aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants.
- Patients who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.
- Patients who are known to have, or suspected to have, an allergic reaction to materials contained in the system.
- Patients who have ever developed a serotonin syndrome and are currently taking any drug known to affect the levels of serotonin in the body [e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs)] should not undergo placement of the device.
- Patients who are pregnant or breast-feeding.
- Subjects with Severe cardiopulmonary disease or other serious organic disease which might include known history of coronary artery disease, Myocardial infarction within the past 6 months, poorly-controlled hypertension, required use of NSAIDs
- Subjects who have tested positive for H. Pylori.
- Subjects taking medications on specified hourly intervals that may be affected by changes to gastric emptying, such as anti-seizure or anti-arrhythmic medications
- Subjects who are taking corticosteroids, immunosuppressants, and narcotics
- Subjects who are taking diet pills
- Use of an intragastric device prior to this study due to the potential increase in risk associated with implantation of a balloon in a previously instrumented and possibly scarred stomach.
- Participation in any clinical study which could affect weight loss within the past 6 months due to the potential to confound findings.
- Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease.
- Pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD), pneumonia or cancer.
- Diagnosis of autoimmune connective tissue disorder (e.g. lupus, erythematous, scleroderma) or immunocompromised.
- Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition, in the opinion of the investigator because of an increased risk profile.
- Specific diagnosed genetic or hormonal cause for obesity such as hypothyroidism or Prader Willi syndrome
- Eating disorders including night eating syndrome (NES), bulimia, binge eating disorder, or compulsive overeating
- Known history of endocrine disorders affecting weight
Sites / Locations
- University of Chicago
- Surgical Specialists of Louisiana
- Endoscopic MicroSurgery Associates
- Brigham and Womans Hospital
- Mayo Clinic
- NY Manhattan VA Hospital
- Ohio State University
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Spatz3 Adjustable Balloon
Control
Arm Description
Spatz3 Adjustable Balloon with Dietary and exercise counselling
Dietary and Exercise counselling
Outcomes
Primary Outcome Measures
Percent Change in Total Body Weight (%TBL) .
The mean %TBL in the Spatz3 group should exceed the %TBL control group by 4.5%.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02812160
Brief Title
Spatz Adjustable Balloon for Obesity (SABO)
Acronym
SABO
Official Title
A Randomized, Controlled, Multicenter Study Comparing the Spatz3 Adjustable Balloon System Plus Diet and Exercise to Diet and Exercise Alone
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
September 12, 2016 (Actual)
Primary Completion Date
October 2018 (Actual)
Study Completion Date
January 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Spatz FGIA, Inc
4. Oversight
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether the Spatz3 Adjustable balloon, a non-surgical device, is effective in the treatment of obesity.
Detailed Description
Device Name: Spatz3 Adjustable Balloon System® (Spatz3) Clinical Phase: Pivotal Trial Design: Multicenter open-label randomized controlled trial Trial Participants: Adults, ages 22-65, with a BMI ≥ 30 and < 40 who have failed to achieve and maintain weight-loss with a weight control program Control group: Supervised diet and exercise Planned sample size: 282 subjects randomized 2:1 to device/control study treatment duration: 32 weeks Primary endpoint: Percent change in total body weight (%TBL) at 32 weeks
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
weight loss
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
288 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Spatz3 Adjustable Balloon
Arm Type
Active Comparator
Arm Description
Spatz3 Adjustable Balloon with Dietary and exercise counselling
Arm Title
Control
Arm Type
No Intervention
Arm Description
Dietary and Exercise counselling
Intervention Type
Device
Intervention Name(s)
Spatz3 Adjustable Balloon
Intervention Description
An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
Primary Outcome Measure Information:
Title
Percent Change in Total Body Weight (%TBL) .
Description
The mean %TBL in the Spatz3 group should exceed the %TBL control group by 4.5%.
Time Frame
32 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 22 - 65
BMI ≥ 30 and <40
Willingness to comply with the substantial lifelong dietary restrictions required by the procedure
History of obesity (BMI ≥ 30) for at least 2 years
History of failure with non-surgical weight loss methods
Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory tests, completing diet counseling
Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete all routine follow- up visits
Ability to give informed consent
Women of childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods. Acceptable birth control methods are limited to hormonal contraceptives (oral, flexible vaginal ring, skin patch, injection), diaphragms, IUDs, condoms with or without spermicide, and voluntary abstinence. The method of birth control must be documented and verified at follow-up. Should a treatment arm subject become pregnant during the implantation period, the balloon will be extracted during the second trimester - the timing of which will be determined via consultation with the subject's obstetrician.
Exclusion Criteria:
Prior gastrointestinal surgery with sequelae, i.e. obstruction, and/or adhesive peritonitis or known abdominal adhesions.
Prior open or laparoscopic bariatric surgery.
Prior surgery of any kind on the esophagus, stomach or any type of hiatal hernia surgery.
Any inflammatory disease of the gastrointestinal tract including esophagitis, Barrett's esophagus, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease.
Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses.
A gastric mass.
A hiatal hernia > 2cm or severe or intractable gastro-esophageal reflux symptoms.
Acid reflux symptoms to any degree that require more than one medication for symptom control.
A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the balloon alongside the endoscope.
Achalasia or any other severe esophageal motility disorder that may pose a safety risk during the removal of the device
Severe coagulopathy.
Insulin-dependent diabetes (either Type 1 or Type 2) or a significant likelihood of requiring insulin treatment in the following 12 months.
Subjects with any serious health condition unrelated to their weight that would increase the risk of endoscopy
Chronic abdominal pain
Motility disorders of the GI tract such as gross esophageal motility disorders, gastroparesis or intractable constipation
Hepatic insufficiency or cirrhosis
Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with follow up visits and removal of the device after 8 months.
Alcoholism or drug addiction.
Patients unwilling to participate in an established medically-supervised diet and behavior modification program, with routine medical follow-up.
Patients receiving daily prescribed treatment with aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants.
Patients who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant.
Patients who are known to have, or suspected to have, an allergic reaction to materials contained in the system.
Patients who have ever developed a serotonin syndrome and are currently taking any drug known to affect the levels of serotonin in the body [e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs)] should not undergo placement of the device.
Patients who are pregnant or breast-feeding.
Subjects with Severe cardiopulmonary disease or other serious organic disease which might include known history of coronary artery disease, Myocardial infarction within the past 6 months, poorly-controlled hypertension, required use of NSAIDs
Subjects who have tested positive for H. Pylori.
Subjects taking medications on specified hourly intervals that may be affected by changes to gastric emptying, such as anti-seizure or anti-arrhythmic medications
Subjects who are taking corticosteroids, immunosuppressants, and narcotics
Subjects who are taking diet pills
Use of an intragastric device prior to this study due to the potential increase in risk associated with implantation of a balloon in a previously instrumented and possibly scarred stomach.
Participation in any clinical study which could affect weight loss within the past 6 months due to the potential to confound findings.
Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease.
Pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD), pneumonia or cancer.
Diagnosis of autoimmune connective tissue disorder (e.g. lupus, erythematous, scleroderma) or immunocompromised.
Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition, in the opinion of the investigator because of an increased risk profile.
Specific diagnosed genetic or hormonal cause for obesity such as hypothyroidism or Prader Willi syndrome
Eating disorders including night eating syndrome (NES), bulimia, binge eating disorder, or compulsive overeating
Known history of endocrine disorders affecting weight
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Barham AbuDayyeh, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christopher C Thompson, MD
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Surgical Specialists of Louisiana
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70001
Country
United States
Facility Name
Endoscopic MicroSurgery Associates
City
Towson
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States
Facility Name
Brigham and Womans Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
NY Manhattan VA Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10010
Country
United States
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
34793746
Citation
Abu Dayyeh BK, Maselli DB, Rapaka B, Lavin T, Noar M, Hussan H, Chapman CG, Popov V, Jirapinyo P, Acosta A, Vargas EJ, Storm AC, Bazerbachi F, Ryou M, French M, Noria S, Molina D, Thompson CC. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021 Nov 27;398(10315):1965-1973. doi: 10.1016/S0140-6736(21)02394-1. Epub 2021 Nov 15. Erratum In: Lancet. 2021 Nov 27;398(10315):1964.
Results Reference
derived
Learn more about this trial
Spatz Adjustable Balloon for Obesity (SABO)
We'll reach out to this number within 24 hrs